Temporal progression of the distribution of Streptococcus pneumoniae serotypes causing invasive pneumococcal disease in Galicia (Spain) and its relationship with resistance to antibiotics (period 2011–2021)

  1. Losada-Castillo, Isabel
  2. Santiago-Pérez, Isolina
  3. Juiz-Gonzalez, Pedro Miguel
  4. Méndez-Lage, Susana
  5. Purriños-Hermida, María Jesús
  6. Malvar, Alberto
  7. Agulla-Budiño, José Andrés
Revista:
Enfermedades infecciosas y microbiologia clinica (English ed.)

ISSN: 2529-993X

Ano de publicación: 2024

Volume: 42

Número: 4

Páxinas: 179-186

Tipo: Artigo

DOI: 10.1016/J.EIMCE.2023.04.012 GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Enfermedades infecciosas y microbiologia clinica (English ed.)

Resumo

Introduction: Streptococcus pneumoniae causes serious diseases in the susceptible population. The 13-valent pneumococci conjugate vaccine (PCV13) was included in the children's calendar in 2011. The objective of the study was to analyze the evolution of pneumococcal serotypes and their resistance after PCV13.Methods: This study included the pneumococci serotyped in Galicia in 2011-2021. Antibiotic susceptibility was analyzed following EUCAST criteria. The data was analyzed in 3 sub-periods: initial (2011-2013), middle (2014-2017) and final (2018-2021). The prevalence of serotypes and their percentage of resistance to the most representative antibiotics were calculated.Results: A total of 2.869 isolates were included. Initially, 42.7% isolates presented capsular types included in PCV13, compared to 15.4% at the end. Those included in PCV20 and not in PCV13 and PCV15 were 12.5% at baseline and 41.3% at the end; 26.4% of the isolates throughout the study had serotypes not included in any vaccine. The prevalence of serotype 8 multiplied almost by 8 and that of 12F tripled. The 19A serotype was initially the most resistant, while the resistance of serotypes 11A and 15A increased throughout the study.Conclusions: The introduction of PCV13 in the pediatric population determined a change in pneumococcal serotypes towards those included in PCV20 and those not included in any vaccine. Serotype 19A was initially the most resistant and the 15A, not included in any vaccine, deserves special follow-up. Serotype 8, which increased the most, did not show remarkable resistance.

€ Ver financiamento

Información de financiamento

Financiadores

Referencias bibliográficas

  • Hausdorff, (2005), Lancet Infect Dis, 5, pp. 83, 10.1016/S1473-3099(05)70083-9
  • Geno, (2015), Clin Microbiol Rev, 28, pp. 871, 10.1128/CMR.00024-15
  • Troeger, (2018), Lancet Infect Dis, 18, pp. 1191, 10.1016/S1473-3099(18)30310-4
  • Vacinación fronte ao pneumococo (estudo piloto) Instrucción. 2011. Vacinación pneumococo (estudo piloto) 2011 [Accessed 11 January 2023]. Available from: https://www.sergas.es/Saude-publica/Documents/2350/Instruci%C3%B3n%20pneumococo%20piloto%202011_galego.pdf.
  • Méndez-Lage, (2015), Enferm Infecc Microbiol Clin, 33, pp. 579, 10.1016/j.eimc.2015.01.010
  • Vacinación antipneumocócica en adultos. Nota_informativa_vacinacion_antipneumococica_2017.pdf [Accessed 11 January 2023]. Available from: https://www.sergas.es/Saude-publica/Documents/4536/Nota_informativa_vacinacion_antipneumococica_2017.pdf.
  • Hanquet, (2022), Emerg Infect Dis, 28, pp. 127, 10.3201/eid2801.210734
  • Càmara, (2017), PLoS One, 12, pp. e0175224, 10.1371/journal.pone.0175224
  • Houseman, (2017), Emerg Infect Dis, 23, pp. 122, 10.3201/eid2301.160897
  • Sheppard, (2016), Eurosurveillance, 21, 10.2807/1560-7917.ES.2016.21.50.30423
  • Porter, (2014), J Vis Exp, 91, pp. 51747
  • EUCAST: Clinical breakpoints and dosing of antibiotics [Accessed 11 January 2023]. Available from: https://www.eucast.org/clinical_breakpoints.
  • Buades, (2021), Vaccines, 9, pp. 93, 10.3390/vaccines9020093
  • Silva-Costa, (2021), Microorganisms, 9, pp. 1016, 10.3390/microorganisms9051016
  • Ladhani, (2018), Lancet Infect Dis, 18, pp. 441, 10.1016/S1473-3099(18)30052-5
  • Nakano, (2020), Vaccine, 38, pp. 1818, 10.1016/j.vaccine.2019.12.022
  • Moore, (2015), Lancet Infect Dis, 15, pp. 301, 10.1016/S1473-3099(14)71081-3
  • Richter, (2014), Antimicrob Agents Chemother, 58, pp. 6484, 10.1128/AAC.03344-14
  • Fernández-Delgado, (2021), Microorganisms, 9, pp. 2245, 10.3390/microorganisms9112245
  • Deloria Knoll, (2021), Microorganisms, 9, pp. 742, 10.3390/microorganisms9040742
  • De Miguel, (2021), Clin Infect Dis, 73, pp. e3778, 10.1093/cid/ciaa1483
  • Sá-Leão, (2011), J Clin Microbiol, 49, pp. 1369, 10.1128/JCM.01763-10
  • Brueggemann, (2003), J Infect Dis, 187, pp. 1424, 10.1086/374624
  • Nakano, (2019), Antimicrob Agents Chemother, 63, pp. e02579, 10.1128/AAC.02579-18